Pegasys + Ribavirin data presented by Schering & the FDA at the FDA Hearing in December 2001


Click here to start


Table of Contents

Peginterferon alfa-2a (40KD) (PEGASYSĘ) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

Background

Study Aims

Study Design (1)

Study Design (2)

Primary Endpoint

Main Inclusion Criteria

Main Exclusion Criteria

Patient Characteristics

Results: SVR Genotype 1

Results: SVR Genotype 1 Low Viral Titre

Results: SVR Genotype 1 High Viral Titre

Results: SVR Genotype Non-1

Sustained Virologic Response: Effect of Cirrhosis

Rate of Withdrawal From Treatment

Ribavirin Discontinuations for Adverse Events / Lab Abnormalities

Serious Adverse Events

Summary (1)

Summary (2)

Summary (3)

Study Countries

Home Page: http://www.natap.org

Download presentation source